Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Learn how an algorithm could be used to personalize dosing schedules for IVIg.
Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
Learn how an algorithm could be used to personalize dosing schedules for IVIg.
Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.
Discover the results of two recent clinical studies of IVIg treatments for CIDP.
National Hospital for Neurology and Neurosurgery, Queen Square, London
National Hospital for Neurology and Neurosurgery, Queen Square, London
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.
Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.